Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects

• Published in: Drugs in R&D Vol. 24; no. 3; pp. 465 - 476
• Main Authors: Ni, Shumao, Ma, Sheng, Yu, Yingying, Yu, Zhenwen, Zhu, Yujia, Sun, Xiaofen, Li, Lin, Sun, Caixia, Wang, Hui, Peng, Peng, Gu, Zheming, Zhang, Hua, Wu, Frank, Miao, Liyan, Fan, Jean
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2024; Springer Nature B.V; Adis, Springer Healthcare
• Subjects: Administration, Oral; Adult; Biotransformation; Breast cancer; Carbon Radioisotopes; Clinical trials; CTR; CTR20212852; Drug dosages; Drug interactions; Enzymes; Feces; Feces - chemistry; Growth factors; Half-Life; Healthy Volunteers; Humans; Internal Medicine; Kinases; Male; Medical prognosis; Medicine; Medicine & Public Health; Metabolism; Metabolites; Molecules; Original; Original Research Article; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - urine; Pyridines; Triazoles; Urine; Young Adult; United Kingdom > UK; United States > US; China

Background and Objective Tinengotinib, a novel multi-target small molecule kinase inhibitor, is currently undergoing phase II clinical trial in the USA and China. The purpose of this open-label study was to investigate the absorption, metabolism, and excretion of [ 14 C]tinengotinib following a sing...